oci ly19  (ATCC)

Journal: ImmunoTargets and Therapy

Article Title: The Dual Mechanism of Action of CO-005 Overcomes CD20 Resistance in Diffuse Large B-Cell Lymphoma

doi: 10.2147/ITT.S572396

Figure Lengend Snippet: CO-005 triggers receptor capping and intracellular signaling events associated with type II anti-CD20 antibodies. (A) NU-DUL-1, (B) ULA, (C) , SU-DHL-10 and (D) OCI-LY19 cells treated with 1 µg/mL CO-005, rituximab (RTX), or obinutuzumab (OBZ) for 3 or 24 hours exhibit distinct patterns of CD47 and CD20 clustering. Receptor distribution was visualized by confocal microscopy following immunofluorescence staining. Scale bar 10 µm. Cellular stress profiling was measured as following (E) Intracellular calcium flux in lymphoma cells treated with 1 µg/mL of the indicated antibodies or isotype control for 3 hours, measured by Fluo-4 AM and flow cytometry. (F) Reactive oxygen species (ROS) levels following antibody treatment (1 µg/mL, 3 hours), assessed by CellROX Green and flow cytometry. (G) Mitochondrial membrane potential (MMP) after CO-005 treatment (0.1 or 1 µg/mL) for 3 hours, determined by TMRM staining. CCCP served as a positive control for mitochondrial depolarization. (H) Effect of actin polymerization inhibition on CO-005 – induced cell death following cytochalasin pretreatment (20 µM, 15 min), measured by Annexin V and 7-AAD staining. Data represent the mean ± SD. Significance was determined by ANOVA analysis *, P < 0.01 compared to the sample treated with CO-005 or as indicated in the figure; ns indicates not significant. All experiments were performed independently three times (n = 3). MFI, mean fluorescence intensity.

Article Snippet: ULA (ACC-267), Riva (ACC-585), OCI-LY18 (ACC-699), OCI-LY19 (ACC-528), and SU-DHL-10 (ACC-576) were obtained from the Leibniz Institute DSMZ–German Collection of Microorganisms and Cell Cultures (DSMZ).

Techniques: Confocal Microscopy, Immunofluorescence, Staining, Control, Flow Cytometry, Membrane, Positive Control, Inhibition, Fluorescence

Journal: ImmunoTargets and Therapy

Article Title: The Dual Mechanism of Action of CO-005 Overcomes CD20 Resistance in Diffuse Large B-Cell Lymphoma

doi: 10.2147/ITT.S572396

Figure Lengend Snippet: CO-005 shifts the phagocytic balance by enhancing “eat me” and promoting macrophage- mediated clearance. ( A ) Surface Calreticulin exposure was assessed in a panel of lymphoma cell lines (NU-DUL-1, OCI-LY18, ULA, SU-DHL-6, SU-DHL-10 and Daudi) following treatment with CO-005, Rituximab (RTX), or Obinutuzumab (OBZ) for 3 hours; Doxorubicin served as a positive control. Calreticulin expression is shown relative to isotype control. (B) Phagocytosis activity of CO-005 or RTX was measured using CellTrace-labeled NU-DUL-1 and OCI-LY19 cells co-cultured with DiO-labeled RAW264.7 macrophages for 2 hours. Phagocytosed cells were quantified as %CellTrace+DiO+ by flow cytometry. Data represent the mean ± SD. Significance was determined by ANOVA analysis *, P < 0.01 compared to the sample treated with CO-005; ns indicates not significant. All experiments were performed independently three times (n = 3).

Article Snippet: ULA (ACC-267), Riva (ACC-585), OCI-LY18 (ACC-699), OCI-LY19 (ACC-528), and SU-DHL-10 (ACC-576) were obtained from the Leibniz Institute DSMZ–German Collection of Microorganisms and Cell Cultures (DSMZ).

Techniques: Positive Control, Expressing, Control, Activity Assay, Labeling, Cell Culture, Flow Cytometry

Journal: ImmunoTargets and Therapy

Article Title: The Dual Mechanism of Action of CO-005 Overcomes CD20 Resistance in Diffuse Large B-Cell Lymphoma

doi: 10.2147/ITT.S572396

Figure Lengend Snippet: CO-005 demonstrates potent anti-lymphoma activity across multiple xenograft models. (A) Experimental timeline for the xenograft study. Mice were inoculated subcutaneously with 1.5 × 10 6 cancer cells (red arrow, Day 0). Treatment injections (blue arrows) were administered intraperitoneally (i.p.) twice weekly, starting when tumors reached a mean volume of 150 mm 3 , for a total of three weeks. (B–D) Tumor growth (left) and survival (right) outcomes in three xenograft models: NU-DUL-1 (B) : Mice were treated with CO-005 (5 mg/kg), RTX (5 mg/kg), or isotype control (5 mg/kg), n = 6. Daudi (C) : Mice received CO-005 at 1 mg/kg or 5 mg/kg, RTX at 5 mg/kg, or a combination of CO-005 (1 mg/kg) and RTX (5 mg/kg), or isotype control (5 mg/kg), n= 5. OCI-LY19 (D) : Mice were treated with CO-005 (5 mg/kg), RTX (5 mg/kg), or isotype control (5 mg/kg), n= 6. Tumor volumes were measured biweekly by caliper and calculated as (length × width 2 )/2. Data represents the mean ± S.D, *p<0.01 (Mann–Whitney U -test), compared to the sample treated with Isotype control at the indicated day (endpoint before control animals are sacrificed); ns indicates not significant. n= animals per treatment group. Survival was monitored until the end of study, *p<0.01 (log-rank (Mantel- Cox) test.

Article Snippet: ULA (ACC-267), Riva (ACC-585), OCI-LY18 (ACC-699), OCI-LY19 (ACC-528), and SU-DHL-10 (ACC-576) were obtained from the Leibniz Institute DSMZ–German Collection of Microorganisms and Cell Cultures (DSMZ).

Techniques: Activity Assay, Control, MANN-WHITNEY